Leadership & Management
Menarini names first female to lead ANZ business
Menarini has shattered a glass ceiling in Australia and New Zealand, appointing its first-ever female General Manager, Kelly Turner. The […]
MoreLeadership & Management
Leadership shift sets Biogen ANZ on course for next-phase growth
Biogen has turned a new page in its Australia and New Zealand (ANZ) leadership, appointing Alice Tien, currently at the […]
MoreLeadership & Management
The triple squeeze on leaders and a messy middle: New future of work report
At a time where the healthcare and life sciences sector is being pushed to reinvent itself, Vanessa Meikle, CEO and […]
MoreLeadership & Management
Rare cancer advocate steps up as PVI President with HTA reform in her sights
The Patient Voice Initiative (PVI) has found its new President: Sarah McGoram, a Canberra-based mother, school teacher, and rare cancer […]
MoreLeadership & Management
Crowe charts new course for Cardinal Health APAC
Cardinal Health has announced a key leadership transition as it sharpens focus on the dynamic Asia Pacific region. Jane Crowe, […]
MoreLeadership & Management
Medicines Australia taps cultural strategist to lead communications amid HTA reform push
Medicines Australia has appointed Rachael Coghlan as its new Communications Director, adding to its Executive Team as the organisation ramps […]
MoreLeadership & Management
New Medicines Australia policy leader critical to HTA reforms
Medicines Australia has appointed Dr Melanie Shakespear into a newly created senior leadership role, signalling a bold step forward in […]
MoreLeadership & Management
New Medicines Australia Chair critical to HTA reforms
Former MTPConnect Chair, Sue MacLeman, is taking the reins as Chair of Medicines Australia, bringing three decades of firepower in […]
MoreLeadership & Management
Ronne shatters barriers as ASO’s first female CEO in over four decades: IWD 2025
As the first female CEO of the Australian Society of Ophthalmologists (ASO) in its 43-year history, Katrina Ronne stands at […]
MoreLeadership & Management
‘We don’t need to choose’: The best advice that shaped Organon’s Asia Pacific leader – IWD 2025
The road to true gender equity is neither straight nor smooth – it is carved by persistence, resilience, and an […]
MoreRecent Posts in Pharma, MedTech & Biotech
CEO roundtable to tackle private health deadlock
September 1, 2025
in News - MedTech & Diagnostics
Rare cancer patients pay the price of policy paralysis: New report
September 1, 2025
in News - Pharmaceuticals
PBS listing delivers first IL-4/IL-13 inhibitor for young children with severe asthma
September 1, 2025
in News - Pharmaceuticals
Pfizer’s pneumococcal vaccine funded after a blurry 1000+ days
September 1, 2025
in News - Pharmaceuticals
Second only to breast cancer: Women face rising blood cancer rates as funding lags decades behind
September 1, 2025
in News - Pharmaceuticals
Opposition and Independents turn up the heat on HTA Review delays
August 29, 2025
in News - Pharmaceuticals
Boehringer Ingelheim tops pharma reputation rankings in ANZ, with Sanofi and Pfizer in close pursuit
August 29, 2025
in News - Pharmaceuticals
Ophthalmologists look to technology to bridge gaps in vision impairment: Roche report
August 29, 2025
in News - Pharmaceuticals
Follow Us
Partner with us
News - MedTech & Diagnostics
CEO roundtable to tackle private health deadlock
Australia’s largest medical indemnity provider representing 95,000 doctors, Avant Mutual, is stepping into the private healthcare policy battlefield, convening 36 […]
MoreNews - Pharmaceuticals
Rare cancer patients pay the price of policy paralysis: New report
Rare Cancers Australia (RCA) is set to release a new report exposing the staggering disparities faced by Australians with rare […]
MoreNews - Pharmaceuticals
PBS listing delivers first IL-4/IL-13 inhibitor for young children with severe asthma
From 1 September, children aged 6–11 years with severe and uncontrolled asthma driven by type 2 inflammation will have access […]
MoreNews - Pharmaceuticals
Pfizer’s pneumococcal vaccine funded after a blurry 1000+ days
From 1 September, Pfizer’s Prevenar 20 (PCV20) officially enters the National Immunisation Program (NIP), becoming the only funded 20-valent pneumococcal […]
More